{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T18:49:58Z","timestamp":1791744598452,"version":"4.3.4"},"reference-count":46,"publisher":"Oxford University Press (OUP)","issue":"7","license":[{"start":{"date-parts":[[2025,5,19]],"date-time":"2025-05-19T00:00:00Z","timestamp":1747612800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"ALF-grant and R&D funds"},{"name":"Skobranschens Utvecklingsfond"},{"DOI":"10.13039\/501100004359","name":"Swedish Research Council","doi-asserted-by":"publisher","award":["2021-02189"],"award-info":[{"award-number":["2021-02189"]}],"id":[{"id":"10.13039\/501100004359","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004359","name":"Swedish Research Council","doi-asserted-by":"publisher","award":["2024-03161"],"award-info":[{"award-number":["2024-03161"]}],"id":[{"id":"10.13039\/501100004359","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004359","name":"Swedish Research Council","doi-asserted-by":"publisher","award":["2021-00980"],"award-info":[{"award-number":["2021-00980"]}],"id":[{"id":"10.13039\/501100004359","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,6,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Denosumab is a potent antagonist of RANKL and is widely used to treat severe postmenopausal osteoporosis. Using high-resolution mass spectrometry (HRMS), we aimed to identify molecular mediators associated with the rapid reactivation of osteoclasts following discontinuation of denosumab. In a previously reported randomized controlled trial, 64 patients undergoing uncemented total hip arthroplasty were randomized to receive 2 doses of 60\u00a0mg denosumab or placebo, administered 1-3 d and 6 mo postoperatively. Serum samples were analyzed using untargeted HRMS coupled with liquid chromatography, and bone turnover markers were assessed. Data were evaluated using linear mixed-effects models and machine learning techniques. After surgery, 83 metabolite features showed significant concentration changes (p\u2009&amp;lt;\u2009.0001). Denosumab-treated patients exhibited increased levels of the dipeptides di-L-phenylalanine, phenylalanylleucine, and alpha-Asp-Phe, and decreased levels of fibrinopeptide A and related peptides 24 mo after surgery. The oxidized peptide AP(Ox)GDRGEP(Ox)GPP(Ox)GP, derived from the collagen type I alpha 1 chain (COL1A1) and referred to as COL1A1-OxP, showed a strong correlation with the bone formation marker procollagen type 1 amino-terminal propeptide (P1NP) (p\u2009=\u20094.4E\u221283). Similarly, the tripeptide DL-alpha-aspartyl-DL-valyl-DL-proline (DVP) correlated highly with the bone resorption marker carboxy-terminal telopeptide of type 1 collagen (CTX) (p\u2009=\u20091.1E\u2212222). P1NP and CTX levels were suppressed at 3, 6, and 12 mo postoperatively but exceeded baseline levels by 24 mo. Global metabolic shifts were observed postoperatively, with distinct profiles between treatment groups. The observed increase in specific dipeptides may reflect mechanisms contributing to rebound bone loss following denosumab withdrawal. Fibrinopeptide A and its analogs may play a protective role, while COL1A1-OxP and DVP represent potential new markers of bone turnover. These findings suggest metabolomics-based biomarkers could aid clinical decision-making by allowing earlier detection of rebound effects and guiding individualized treatment strategies after denosumab therapy.<\/jats:p>\n               <jats:p>Clinical trial registration number: ClinicalTrials.gov, NCT01630941 (URL: https:\/\/clinicaltrials.gov\/); European Union Clinical Trials Register (EU CTR), EudraCT No. 2011-001481-18 (https:\/\/www.clinicaltrialsregister.eu\/)<\/jats:p>","DOI":"10.1093\/jbmrpl\/ziaf091","type":"journal-article","created":{"date-parts":[[2025,5,19]],"date-time":"2025-05-19T12:32:43Z","timestamp":1747657963000},"source":"Crossref","is-referenced-by-count":2,"title":["Uncemented hip arthroplasty and denosumab: increased postoperative dipeptide concentrations and identification of potential new bone turnover biomarkers"],"prefix":"10.1093","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0680-1410","authenticated-orcid":false,"given":"Kim","family":"Kultima","sequence":"first","affiliation":[{"name":"Department of Medical Sciences, Clinical Chemistry, Uppsala University , 751 85 Uppsala ,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saman Hosseini","family":"Ashtiani","sequence":"additional","affiliation":[{"name":"Department of Medical Sciences, Clinical Chemistry, Uppsala University , 751 85 Uppsala ,","place":["Sweden"]},{"name":"Science for Life Laboratory, Department of Biochemistry and Biophysics, Stockholm University , 106 91 Stockholm,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ida","family":"Erngren","sequence":"additional","affiliation":[{"name":"Department of Medical Sciences, Clinical Chemistry, Uppsala University , 751 85 Uppsala ,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Payam Emami","family":"Khoonsari","sequence":"additional","affiliation":[{"name":"Department of Medical Sciences, Clinical Chemistry, Uppsala University , 751 85 Uppsala ,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henrik","family":"Carlsson","sequence":"additional","affiliation":[{"name":"Department of Medical Sciences, Clinical Chemistry, Uppsala University , 751 85 Uppsala ,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"Herman","sequence":"additional","affiliation":[{"name":"Department of Medical Sciences, Clinical Chemistry, Uppsala University , 751 85 Uppsala ,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Freyhult","sequence":"additional","affiliation":[{"name":"Department of Cell and Molecular Biology, Uppsala University , 751 24 Uppsala ,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans","family":"Mallmin","sequence":"additional","affiliation":[{"name":"Department of Surgical Sciences\/Orthopaedics, Uppsala University , 751 85 Uppsala ,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nils P","family":"Hailer","sequence":"additional","affiliation":[{"name":"Department of Surgical Sciences\/Orthopaedics, Uppsala University , 751 85 Uppsala ,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,5,19]]},"reference":[{"issue":"18","key":"2025062622324044100_ref1","doi-asserted-by":"publisher","first-page":"2412","DOI":"10.1101\/gad.13.18.2412","article-title":"RANK is essential for osteoclast and lymph node development","volume":"13","author":"Dougall","year":"1999","journal-title":"Genes Dev"},{"issue":"2","key":"2025062622324044100_ref2","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1016\/j.jocd.2008.02.002","article-title":"Clinical potential of RANKL inhibition for the management of postmenopausal osteoporosis and other metabolic bone diseases","volume":"11","author":"Delmas","year":"2008","journal-title":"J Clin Densitom"},{"issue":"8","key":"2025062622324044100_ref3","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1056\/NEJMoa044459","article-title":"Denosumab in postmenopausal women with low bone mineral density","volume":"354","author":"McClung","year":"2006","journal-title":"N Engl J Med"},{"issue":"8","key":"2025062622324044100_ref4","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1056\/NEJMoa0809493","article-title":"Denosumab for prevention of fractures in postmenopausal women with osteoporosis","volume":"361","author":"Cummings","year":"2009","journal-title":"N Engl J Med"},{"issue":"6","key":"2025062622324044100_ref5","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.1002\/jbmr.3110","article-title":"Clinical features of 24 patients with rebound-associated vertebral fractures after denosumab discontinuation: systematic review and additional cases","volume":"32","author":"Anastasilakis","year":"2017","journal-title":"J Bone Miner Res"},{"key":"2025062622324044100_ref6","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.atherosclerosis.2018.03.007","article-title":"CD137: a checkpoint regulator involved in atherosclerosis","volume":"272","author":"S\u00f6derstr\u00f6m","year":"2018","journal-title":"Atherosclerosis."},{"key":"2025062622324044100_ref7","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgaa756","article-title":"Fracture risk and management of discontinuation of denosumab therapy: a systematic review and position statement by ECTS","volume":"26","author":"Tsourdi","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"issue":"7","key":"2025062622324044100_ref8","doi-asserted-by":"publisher","first-page":"1501","DOI":"10.2106\/00004623-200607000-00011","article-title":"Serum levels of osteoprotegerin and receptor activator of nuclear factor-kappaB ligand as markers of periprosthetic osteolysis","volume":"88","author":"Granchi","year":"2006","journal-title":"J Bone Joint Surg Am"},{"issue":"2","key":"2025062622324044100_ref9","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1002\/jbmr.3883","article-title":"Denosumab prevents early periprosthetic bone loss after uncemented total hip arthroplasty: results from a randomized placebo-controlled clinical trial","volume":"35","author":"Nystr\u00f6m","year":"2020","journal-title":"J Bone Miner Res"},{"key":"2025062622324044100_ref10","doi-asserted-by":"publisher","first-page":"709","DOI":"10.2340\/17453674.2022.4537","article-title":"Denosumab prevents acetabular bone loss around an uncemented cup: analysis of secondary outcomes in a randomized controlled trial","volume":"93","author":"Kiritopoulos","year":"2022","journal-title":"Acta Orthop"},{"issue":"20","key":"2025062622324044100_ref11","doi-asserted-by":"publisher","first-page":"1857","DOI":"10.2106\/JBJS.J.01646","article-title":"The effect of weekly risedronate on periprosthetic bone resorption following total hip arthroplasty: a randomized, double-blind, placebo-controlled trial","volume":"93","author":"Sk\u00f6ldenberg","year":"2011","journal-title":"J Bone Joint Surg Am"},{"issue":"2","key":"2025062622324044100_ref12","doi-asserted-by":"crossref","first-page":"274","DOI":"10.2106\/JBJS.G.01193","article-title":"The effect of a single infusion of zoledronic acid on early implant migration in total hip arthroplasty. A randomized, double-blind, controlled trial","volume":"91","author":"Friedl","year":"2009","journal-title":"J Bone Joint Surg Am"},{"issue":"5","key":"2025062622324044100_ref13","doi-asserted-by":"publisher","first-page":"569","DOI":"10.3109\/17453674.2015.1041846","article-title":"No effect of risedronate on femoral periprosthetic bone loss following total hip arthroplasty. A 4-year follow-up of 61 patients in a double-blind, randomized placebo-controlled trial","volume":"86","author":"Muren","year":"2015","journal-title":"Acta Orthop"},{"key":"2025062622324044100_ref14","doi-asserted-by":"publisher","DOI":"10.1007\/s00198-022-06423-w","article-title":"Effects of denosumab treatment on the expression of receptor activator of nuclear kappa-B ligand (RANKL) and TNF-receptor TNFRSF9 after total hip arthroplasty-results from a randomized placebo-controlled clinical trial","volume":"33","author":"Sk\u00f6ld","year":"2022","journal-title":"Osteoporos Int"},{"issue":"4","key":"2025062622324044100_ref15","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1016\/j.joca.2023.11.019","article-title":"Three decades of advancements in osteoarthritis research: insights from transcriptomic, proteomic, and metabolomic studies","volume":"32","author":"Rai","year":"2024","journal-title":"Osteoarthr Cartil"},{"issue":"7","key":"2025062622324044100_ref16","doi-asserted-by":"publisher","first-page":"2569","DOI":"10.1007\/s10067-020-05511-8","article-title":"A review of applications of metabolomics in osteoarthritis","volume":"40","author":"Li","year":"2021","journal-title":"Clin Rheumatol"},{"issue":"1","key":"2025062622324044100_ref17","doi-asserted-by":"publisher","first-page":"26","DOI":"10.5301\/hipint.5000413","article-title":"Periprosthetic femoral bone loss in total hip arthroplasty: systematic analysis of the effect of stem design","volume":"27","author":"Knutsen","year":"2017","journal-title":"Hip Int"},{"issue":"9","key":"2025062622324044100_ref18","doi-asserted-by":"publisher","first-page":"2541","DOI":"10.1007\/s00198-017-4082-4","article-title":"Use of CTX-I and PINP as bone turnover markers: National Bone Health Alliance recommendations to standardize sample handling and patient preparation to reduce pre-analytical variability","volume":"28","author":"Szulc","year":"2017","journal-title":"Osteoporos Int"},{"issue":"16","key":"2025062622324044100_ref19","doi-asserted-by":"publisher","first-page":"4477","DOI":"10.7150\/thno.26249","article-title":"Integration of magnetic resonance imaging and protein and metabolite CSF measurements to enable early diagnosis of secondary progressive multiple sclerosis","volume":"8","author":"Herman","year":"2018","journal-title":"Theranostics."},{"issue":"21","key":"2025062622324044100_ref20","doi-asserted-by":"publisher","first-page":"2534","DOI":"10.1093\/bioinformatics\/btn323","article-title":"ProteoWizard: open source software for rapid proteomics tools development","volume":"24","author":"Kessner","year":"2008","journal-title":"Bioinformatics."},{"key":"2025062622324044100_ref21","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1007\/978-3-540-78246-9_38","volume-title":"Data Analysis, Machine Learning and Applications","author":"Berthold","year":"2008"},{"issue":"1","key":"2025062622324044100_ref22","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1074\/mcp.M113.031278","article-title":"Automated label-free quantification of metabolites from liquid chromatography-mass spectrometry data","volume":"13","author":"Kenar","year":"2014","journal-title":"Mol Cell Proteomics"},{"issue":"7","key":"2025062622324044100_ref23","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1007\/s11306-017-1213-z","article-title":"Mass spectrometry based metabolomics for in vitro systems pharmacology: pitfalls, challenges, and computational solutions","volume":"13","author":"Herman","year":"2017","journal-title":"Metabolomics."},{"issue":"2","key":"2025062622324044100_ref24","doi-asserted-by":"publisher","DOI":"10.3390\/cells8020084","article-title":"Biochemical differences in cerebrospinal fluid between secondary progressive and relapsing(\u2212)remitting multiple sclerosis","volume":"8","author":"Herman","year":"2019","journal-title":"Cells."},{"issue":"11","key":"2025062622324044100_ref25","doi-asserted-by":"publisher","first-page":"e1005752","DOI":"10.1371\/journal.pcbi.1005752","article-title":"mixOmics: an R package for \u2019omics feature selection and multiple data integration","volume":"13","author":"Rohart","year":"2017","journal-title":"PLoS Comput Biol"},{"issue":"1","key":"2025062622324044100_ref26","doi-asserted-by":"publisher","DOI":"10.18637\/jss.v067.i01","article-title":"Fitting linear mixed-effects models using lme4","volume":"67","author":"Bates","year":"2015","journal-title":"J Stat Softw"},{"issue":"4","key":"2025062622324044100_ref27","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1038\/s41592-019-0344-8","article-title":"SIRIUS 4: a rapid tool for turning tandem mass spectra into metabolite structure information","volume":"16","author":"D\u00fchrkop","year":"2019","journal-title":"Nat Methods"},{"issue":"9","key":"2025062622324044100_ref28","doi-asserted-by":"publisher","first-page":"1466","DOI":"10.1093\/bioinformatics\/bth092","article-title":"TANDEM: matching proteins with tandem mass spectra","volume":"20","author":"Craig","year":"2004","journal-title":"Bioinformatics."},{"key":"2025062622324044100_ref29","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.npep.2018.04.004","article-title":"Spinal injection of newly identified cerebellin-1 and cerebellin-2 peptides induce mechanical hypersensitivity in mice","volume":"69","author":"Sandor","year":"2018","journal-title":"Neuropeptides."},{"key":"2025062622324044100_ref30","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1007\/978-1-4471-5451-8_8","volume-title":"Classic Papers in Orthopaedics","author":"Banaszkiewicz","year":"2014"},{"key":"2025062622324044100_ref31","doi-asserted-by":"publisher","first-page":"101148","DOI":"10.1016\/j.bonr.2021.101148","article-title":"Hypercalcemia following discontinuation of denosumab therapy: a systematic review","volume":"15","author":"Horiuchi","year":"2021","journal-title":"Bone Rep"},{"issue":"3","key":"2025062622324044100_ref32","doi-asserted-by":"publisher","first-page":"162","DOI":"10.3177\/jnsv.68.162","article-title":"Biological functions of antioxidant dipeptides","volume":"68","author":"Ozawa","year":"2022","journal-title":"J Nutr Sci Vitaminol"},{"issue":"11","key":"2025062622324044100_ref33","doi-asserted-by":"publisher","first-page":"2008","DOI":"10.1136\/gutjnl-2019-319811","article-title":"Associations between metabolites and pancreatic cancer risk in a large prospective epidemiological study","volume":"69","author":"Stolzenberg-Solomon","year":"2020","journal-title":"Gut."},{"issue":"1","key":"2025062622324044100_ref34","doi-asserted-by":"publisher","first-page":"123","DOI":"10.3899\/jrheum.200054","article-title":"Phenylalanine is a novel marker for radiographic knee osteoarthritis progression: the MOST study","volume":"48","author":"Zhai","year":"2021","journal-title":"J Rheumatol"},{"issue":"1","key":"2025062622324044100_ref35","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1186\/s12967-021-03169-7","article-title":"Serum metabolomic and lipidomic profiling identifies diagnostic biomarkers for seropositive and seronegative rheumatoid arthritis patients","volume":"19","author":"Luan","year":"2021","journal-title":"J Transl Med"},{"issue":"6","key":"2025062622324044100_ref36","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1001\/jama.2020.22171","article-title":"Diagnosis and treatment of hip and knee osteoarthritis","volume":"325","author":"Katz","year":"2021","journal-title":"JAMA."},{"issue":"2","key":"2025062622324044100_ref37","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1017\/S000711450769936X","article-title":"Amino acids and immune function","volume":"98","author":"Li","year":"2007","journal-title":"Br J Nutr"},{"issue":"1","key":"2025062622324044100_ref38","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/0049-3848(85)90347-0","article-title":"Increased phosphorylation of human fibrinopeptide a under acute phase conditions","volume":"40","author":"Seydewitz","year":"1985","journal-title":"Thromb Res"},{"issue":"1","key":"2025062622324044100_ref39","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1093\/clinchem\/45.1.47","article-title":"Thermal instability of the trimeric structure of the N-terminal propeptide of human procollagen type I in relation to assay technology","volume":"45","author":"Brandt","year":"1999","journal-title":"Clin Chem"},{"key":"2025062622324044100_ref40","volume-title":"Principles of Bone Biology","author":"Bilezikian","year":"2008"},{"issue":"10","key":"2025062622324044100_ref41","doi-asserted-by":"publisher","first-page":"1858","DOI":"10.1002\/jbmr.4098","article-title":"Treatment with Zoledronate subsequent to denosumab in osteoporosis: a randomized trial","volume":"35","author":"S\u00f8lling","year":"2020","journal-title":"J Bone Miner Res"},{"issue":"4","key":"2025062622324044100_ref42","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1093\/jbmr\/zjae023","article-title":"Temporal patterns of osteoclast formation and activity following withdrawal of RANKL inhibition","volume":"39","author":"Kim","year":"2024","journal-title":"J Bone Miner Res"},{"issue":"18","key":"2025062622324044100_ref43","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.167790","article-title":"Reduced osteoprotegerin expression by osteocytes may contribute to rebound resorption after denosumab discontinuation","volume":"8","author":"Fu","year":"2023","journal-title":"JCI Insight."},{"issue":"3","key":"2025062622324044100_ref44","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1007\/s00198-022-06651-0","article-title":"Changes in RANKL and TRAcP 5b after discontinuation of denosumab suggest RANKL mediated formation of osteoclasts results in the increased bone resorption","volume":"34","author":"S\u00f8lling","year":"2023","journal-title":"Osteoporos Int"},{"issue":"5","key":"2025062622324044100_ref45","doi-asserted-by":"publisher","first-page":"1330","DOI":"10.1016\/j.cell.2021.02.002","article-title":"Osteoclasts recycle via osteomorphs during RANKL-stimulated bone resorption","volume":"184","author":"McDonald","year":"2021","journal-title":"Cell."},{"issue":"1","key":"2025062622324044100_ref46","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1097\/BOR.0000000000000853","article-title":"Insights into the molecular landscape of osteoarthritis in human tissues","volume":"34","author":"Katsoula","year":"2022","journal-title":"Curr Opin Rheumatol"}],"container-title":["JBMR Plus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jbmrplus\/advance-article-pdf\/doi\/10.1093\/jbmrpl\/ziaf091\/63233415\/ziaf091.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jbmrplus\/article-pdf\/9\/7\/ziaf091\/63233415\/ziaf091.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jbmrplus\/article-pdf\/9\/7\/ziaf091\/63233415\/ziaf091.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,27]],"date-time":"2025-06-27T02:32:47Z","timestamp":1750991567000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jbmrplus\/article\/doi\/10.1093\/jbmrpl\/ziaf091\/8137679"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,19]]},"references-count":46,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,6,5]]}},"URL":"https:\/\/doi.org\/10.1093\/jbmrpl\/ziaf091","relation":{},"ISSN":["2473-4039"],"issn-type":[{"value":"2473-4039","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,7]]},"published":{"date-parts":[[2025,5,19]]},"article-number":"ziaf091"}}